KR100997463B1 - 난소암 진단용 조성물, 그 키트 및 진단 방법 - Google Patents
난소암 진단용 조성물, 그 키트 및 진단 방법 Download PDFInfo
- Publication number
- KR100997463B1 KR100997463B1 KR1020070042143A KR20070042143A KR100997463B1 KR 100997463 B1 KR100997463 B1 KR 100997463B1 KR 1020070042143 A KR1020070042143 A KR 1020070042143A KR 20070042143 A KR20070042143 A KR 20070042143A KR 100997463 B1 KR100997463 B1 KR 100997463B1
- Authority
- KR
- South Korea
- Prior art keywords
- expression
- less
- ovarian cancer
- apolipoprotein
- expression level
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
특성 | |
연구 환자수 | 263 |
정상 | 61 |
난소낭종 | 84 |
난소암 | 118 |
연구 환자의 연령 (평균 ± S.D.) | 45.81 ± 14.43 |
(범위) | 12-84 |
난소암 환자의 FIGO 병기 | |
I | 27 (22.9%) |
II | 9 (7.6%) |
III | 54 (45.8%) |
IV | 15 (12.7%) |
기타 | 13 (11.0%) |
난소암 환자의 조직학적 분류 | |
Serous | 52 (44.1%) |
Mucinous | 15 (12.7%) |
Endometrioid | 8 (6.8%) |
Clear Cell | 8 (6.8%) |
Granulosa Cell | 4 (3.4%) |
Others | 31 (26.3%) |
Analysts/patients | 정상 대조군 | 난소암 환자 | 난소낭종 | |
Apolipoprotein A1 (ng/㎖) |
mean± SE | 28,091± 3,305 | 2,342.3± 481.7*** | 3,350± 1,040*** |
Median(range) | 12,400 (1,305-60,500) |
450(103.0-38,450) | 830(109-60,500) | |
Hemoglobin (㎍/㎖) |
mean± SE | 687± 121 | 3856.5± 718.6* | 5,216.6± 1,265.7*** |
Median(range) | 53.5(53.5-7,150) | 805(53.5-47,300.0) | 1,335(53.5-92,500) | |
Transthyretin (㎍/㎖) |
mean± SE | 178± 9.4 | 65.1± 4.5*** | 99.9± 8.0*** |
Median(range) | 177(41.6-388.5) | 52(3.435- 261.000) | 90.3(11.5- 499.5) | |
CA125 (U/㎖) |
mean± SE | 35± 20.1 | 456± 57.9*** | 94.7± 46.4** |
Median(range) | 9.3(6.80-1230.) | 200(6.80- 3,475) | 28.2(7.10- 3,915) |
Analysts/ patients |
% | 정상대조군과 난소암환자군 | 정상대조군 및 난소낭종군 과 난소암환자군 | 난소낭종군과 난소암환자군 | 정상대조군과 난소낭종군 |
Apolipoprotein A1 | Sensitivity | 76.3 | 42.8 | 41.4 | 76.3 |
Specificity | 92.5 | 86.8 | 84.7 | 92.5 | |
Hemoglobin | Sensitivity | 73.8 | |||
Specificity | 80.3 | ||||
Transthyretin | Sensitivity | 76.4 | 58.2 | 65.0 | |
Specificity | 95.1 | 83.5 | 86.0 | ||
CA125 | Sensitivity | 72.5 | 68.5 | 42.9 | |
Specificity | 71.4 | 86.5 | 92.9 | ||
Total | Sensitivity | 98.1 | 71.8 | 72.8 | 88.5 |
Specificity | 100 | 74.8 | 62.8 | 92.9 |
Claims (4)
- 삭제
- 삭제
- (a) CA125, 아포지방단백질 A1, 트란스타이레틴, 및 헤모글로빈 각각에 특이적인 항체를 동시에 생물학적 시료와 접촉시켜 항원-항체 복합체를 형성하는 단계;(b) 상기 단계 (a)에서 형성된 항원-항체 복합체의 형성량을 다중 액상 분석법(multiplex liquid array system)으로 검출하여 CA125, 아포지방단백질 A1, 트란스타이레틴, 및 헤모글로빈의 발현양을 측정하는 단계;(c) 상기 단계 (b)에서 측정된 발현양에 대해서i) 아포지방단백질 A1의 발현양이 2572.5ng/ml 미만이거나, 아포지방단백질 A1의 발현양이 2572.5ng/ml 이상이고 트랜스타이레틴의 발현양이 80.5ng/ml 미만이면 난소암으로 판정하고, 아포지방단백질 A1의 발현양이 2572.5ng/ml 이상이고 트랜스타이레틴의 발현양이 80.5ng/ml 이상이면 정상으로 판정하는 단계;ii) CA125 발현양이 105.25㎍/ml 미만이고 트랜스타이레틴의 발현양이 81.25ng/ml 이상이거나, CA125 발현양이 105.25㎍/ml 미만이고 트랜스타이레틴의 발현양이 81.25ng/ml 미만이고 CA125 발현양이 32.65㎍/ml 이상이거나, CA125 발현양이 105.25㎍/ml 이상 210.75㎍/ml 미만이고 아포지방단백질 A1의 발현양 1947.5ng/ml 이상이거나, 또는 CA125 발현양이 210.75㎍/ml 이상이면 난소암으로 판정하고,트랜스타이레틴의 발현양이 81.25ng/ml 미만이고 CA125 발현양이 32.65㎍/ml 미만이거나, CA125 발현양이 105.25㎍/ml 이상 210.75㎍/ml 미만이고 아포지방단백질 A1의 발현양 1947.5ng/ml 미만이면 정상 또는 난소낭종으로 판정하는 단계;ⅲ) CA125 발현양이 10.25㎍/ml 미만이거나, CA125 발현양이 105.25㎍/ml 이상 210.75㎍/ml 미만이며 아포지방단백질 A1의 발현양이 1947.5ng/ml 미만이면 난소낭종으로 판정하고, CA125 발현양이 10.25㎍/ml 이상이고 105.25㎍/ml 미만이거나, CA125 발현양이 210.75㎍/ml 이상이거나, CA125 발현양이 105.25㎍/ml 이상 210.75㎍/ml 미만이며 아포지방단백질 A1의 발현양이 1947.5ng/ml 이상이면 난소암으로 판정하는 단계; 및ⅳ) 아포지방단백질 A1의 발현양이 1300ng/ml 미만이거나, 아포지방단백질 A1의 발현양이 1300ng/ml 이상 2540ng/ml 미만이고 CA125 발현양이 20.85㎍/ml 이상이거나, 아포지방단백질 발현양이 2540ng/ml 이상이고 헤모글로빈 발현양이 2122.5ng/ml 이상이거나, 또는 아포지방단백질 발현양이 2540ng/ml 이상이고 헤모글로빈 발현양이 2122.5ng/ml 미만이고 트랜스타이레틴의 발현양 81.25ng/ml 이상이면 난소낭종으로 판정하고,아포지방단백질 A1의 발현양이 1300ng/ml 이상 2540ng/ml 미만이고, CA125 발현양이 20.85㎍/ml 미만이거나, 또는 아포지방단백질 발현양이 2540ng/ml 이상이고 헤모글로빈 발현양이 2122.5ng/ml 미만이고 트랜스타이레틴의 발현양 81.25ng/ml 미만이면 정상으로 판정하는 단계;를 포함하는 CA125, 아포지방단백질 A1, 트란스타이레틴, 및 헤모글로빈 각각에 특이적인 4가지 항체를 이용하여 항원-항체 복합체의 형성량을 다중 액상 분석법(multiplex liquid array system)으로 한번에 검출하는데 특징이 있는 정상, 난소낭종, 및 난소암의 진단을 위한 정보를 제공하는 방법.
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070042143A KR100997463B1 (ko) | 2007-04-30 | 2007-04-30 | 난소암 진단용 조성물, 그 키트 및 진단 방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070042143A KR100997463B1 (ko) | 2007-04-30 | 2007-04-30 | 난소암 진단용 조성물, 그 키트 및 진단 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080097050A KR20080097050A (ko) | 2008-11-04 |
KR100997463B1 true KR100997463B1 (ko) | 2010-11-30 |
Family
ID=40285107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070042143A KR100997463B1 (ko) | 2007-04-30 | 2007-04-30 | 난소암 진단용 조성물, 그 키트 및 진단 방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100997463B1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006019906A1 (en) * | 2004-07-14 | 2006-02-23 | The Regents Of The University Of California | Biomarker for early detection of ovarian cancer |
WO2007002535A2 (en) | 2005-06-24 | 2007-01-04 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer |
WO2007002264A2 (en) | 2005-06-22 | 2007-01-04 | The Johns Hopkins University | Biomarker for ovarian cancer: ctap3-related proteins |
-
2007
- 2007-04-30 KR KR1020070042143A patent/KR100997463B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006019906A1 (en) * | 2004-07-14 | 2006-02-23 | The Regents Of The University Of California | Biomarker for early detection of ovarian cancer |
WO2007002264A2 (en) | 2005-06-22 | 2007-01-04 | The Johns Hopkins University | Biomarker for ovarian cancer: ctap3-related proteins |
WO2007002535A2 (en) | 2005-06-24 | 2007-01-04 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer |
Also Published As
Publication number | Publication date |
---|---|
KR20080097050A (ko) | 2008-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6630766B2 (ja) | 膵臓癌診断用組成物およびこれを用いた膵臓癌診断方法 | |
US6294349B1 (en) | Method of diagnosing and monitoring malignant breast carcinomas | |
CN112362871B (zh) | 食管癌的生物标志物及其应用 | |
CA2712204A1 (en) | Small cell lung carcinoma biomarker panel | |
CN112345755B (zh) | 乳腺癌的生物标志物及其应用 | |
US12037647B2 (en) | Compositions and methods for detecting pancreatic cancer | |
US20190202930A1 (en) | Methods for treatment of ovarian cancer | |
Tas et al. | Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients | |
US20220254441A1 (en) | Data collection method to be used for classifying cancer life | |
Cui et al. | Carboxypeptidase N1 is anticipated to be a synergy metrics for chemotherapy effectiveness and prognostic significance in invasive breast cancer | |
KR100997463B1 (ko) | 난소암 진단용 조성물, 그 키트 및 진단 방법 | |
CN109116023A (zh) | 一种肺癌标志物抗-mmp12自身抗体及其应用 | |
US5955287A (en) | Method of determining level of biological substances elevated in the presence of cancer and other neoplasms | |
KR101247636B1 (ko) | 편평상피세포암의 진단용 마커 및 이를 포함한 키트 | |
Martinelli et al. | Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer | |
US20140038211A1 (en) | Breast cancer diagnosis using nipple discharge | |
US20220390453A1 (en) | Ovarian cancer biomarker and methods of using same | |
CN111693703B (zh) | Spondin 1和HE4联合用作早期卵巢癌生物标志物以及试剂盒 | |
US20210181200A1 (en) | Ovarian cancer biomarker and methods of using same | |
KR102427057B1 (ko) | 단일섬유종양/혈관주위세포종 전이 진단 또는 예후 분석용 바이오 마커 및 이를 이용한 진단방법 | |
US20230375550A1 (en) | Method for diagnosing breast cancer by using biomarker | |
Deinzer et al. | Comparison of two different methods for CA19-9 antigen determination | |
CA3163199A1 (en) | Ovarian cancer biomarker and methods of using same | |
Chen et al. | PRKAA1 predicts prognosis and is associated with immune characteristics in gastric cancer | |
KR20240068432A (ko) | 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
N231 | Notification of change of applicant | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131120 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141217 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151102 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171113 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181029 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190923 Year of fee payment: 10 |